SEC Filing Summary
Issuer and period: The filing is Access Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2014. This differs from the request metadata, which names Abeona Therapeutics Inc.
Business context
Access described itself as an emerging biopharmaceutical company developing drug-delivery technologies and products. MuGard, its marketed oral-mucositis product, was licensed to partners in the U.S., China, South Korea and, after quarter-end, Europe. ProctiGard received FDA 510(k) marketing clearance in July 2014. Other development and preclinical programs included LexaGard, CobOral and CobaCyte.
Financial results
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Total revenue | $247,000 | $467,000 | $455,000 | $1,691,000 |
| Operating expenses | $950,000 | $2,388,000 | $2,486,000 | $4,115,000 |
| Loss from operations | $703,000 | $1,921,000 | $2,031,000 | $2,424,000 |
| Net income (loss) allocable to common stockholders | ($13,233,000) | $867,000 | ($14,817,000) | $4,221,000 |
| Loss per common share | ($0.51) | $0.03 | ($0.57) | $0.17 |
Revenue shifted from product sales to licensing and royalties after the MuGard U.S. license to AMAG. There were no Access product sales in 2014; royalty revenue was $97,000 for Q2 and $159,000 for the first half. The large 2014 net loss chiefly reflected an $11.7 million Q2 fair-value loss on the preferred-stock derivative liability ($11.1 million for the first half), compared with derivative gains in 2013. This noncash valuation item substantially affected reported earnings.
For the six months, operating cash flow was negative $369,000, versus positive $1.391 million in 2013. Cash and cash equivalents fell to $55,000 at June 30 from $424,000 at year-end. Working capital deficit was $10.969 million, up $2.583 million from December 31, 2013. Total liabilities were $28.642 million, including $8.373 million of accrued preferred dividends, a $12.3 million preferred-stock derivative liability and $5.772 million of deferred revenue. The filing does not report conventional borrowings as a material liability. No gross margin or debt-specific ratio is provided.
Material changes and significant items
- First-half revenue declined to $455,000 from $1.691 million, mainly because Access no longer booked MuGard U.S. product sales following the AMAG licensing arrangement; licensing and royalty revenue increased but did not offset the lost sales.
- Operating expenses declined to $2.486 million from $4.115 million for the first half, reflecting reduced R&D, selling costs, legal fees and staffing, partly offset by higher stock-based compensation. First-half stock-based compensation was $987,000.
- In March 2014, Access announced an exclusive South Korea MuGard license with Hanmi, including an upfront fee and double-digit royalties. In August, it announced a Europe license with Norgine, with up to $10 million in milestones and escalating double-digit royalties; Norgine anticipated a 2015 launch. These are licensing terms, not guaranteed receipts.
- At August 14, 2014, 26.6 million common shares were outstanding. Series A and B preferred shares were convertible into approximately 57.9 million and 20.0 million common shares, respectively; substantial additional dilution was also possible from warrants and options.
Outlook, risks and contingencies
Management expected available capital, MuGard royalties and anticipated license receipts to fund the current operating level into the first quarter of 2015, but said additional funding would be required and could not assure continued operations as a going concern. The filing reports substantial doubt about continuing as a going concern; financing may require equity issuance and dilute existing holders. Management expected continued losses while funding development.
Preferred dividends were unpaid and continued to accrue; the company reported $8.373 million payable at June 30. It also accrued $857,000 in liquidated damages because a registration statement covering certain preferred-conversion shares was not effective. A shareholder-related lawsuit remained on appeal, with oral argument scheduled for September 12, 2014; Access said it would contest the claims. Management reported an unremediated material weakness in financial reporting controls, citing insufficient accounting staff and lack of segregation of duties; disclosure controls were considered ineffective. No other material pending litigation was reported.
Important facts for investors to verify
- Whether subsequent financing, licensing milestone payments and royalties were sufficient to extend the stated Q1 2015 cash runway.
- Actual MuGard sales, royalty receipts and launch progress under the Hanmi and Norgine agreements, including whether milestone payments were earned.
- The assumptions and sensitivity behind the $12.3 million Level 3 preferred-stock derivative valuation and its effect on reported earnings.
- Preferred-dividend and registration-damage obligations, conversion terms, and potential dilution from preferred shares, warrants and options.
- Progress toward remediating the material weakness, and developments in the pending appeal and going-concern risk.